Sascha A Kristian Selected Research

Teichoic Acids

11/2009	Neutrophil antimicrobial defense against Staphylococcus aureus is mediated by phagolysosomal but not extracellular trap-associated cathelicidin.
5/2005	Lack of wall teichoic acids in Staphylococcus aureus leads to reduced interactions with endothelial cells and to attenuated virulence in a rabbit model of endocarditis.
3/2004	Role of teichoic acids in Staphylococcus aureus nasal colonization, a major risk factor in nosocomial infections.
11/2003	Bacterial resistance to antimicrobial host defenses--an emerging target for novel antiinfective strategies?
8/2003	Alanylation of teichoic acids protects Staphylococcus aureus against Toll-like receptor 2-dependent host defense in a mouse tissue cage infection model.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sascha A Kristian Research Topics

Disease

9	Infections 11/2018 - 08/2003
3	Bacterial Infections (Bacterial Infection) 11/2018 - 10/2005
2	Wounds and Injuries (Trauma) 11/2018 - 04/2007
2	Inflammation (Inflammations) 11/2018 - 08/2003
2	Persistent Infection 05/2004 - 08/2003
1	Melanoma (Melanoma, Malignant) 01/2019
1	Neoplasms (Cancer) 01/2019
1	Pneumococcal Infections 01/2016
1	Sepsis (Septicemia) 01/2016
1	Pneumonia (Pneumonitis) 01/2016
1	Muscle Cramp (Cramp) 11/2009
1	Wound Infection (Wound Infections) 04/2007
1	Necrotizing Fasciitis 02/2006
1	Endocarditis 05/2005
1	Cross Infection (Nosocomial Infection) 03/2004

Drug/Important Bio-Agent (IBA)

5	Teichoic AcidsIBA 11/2009 - 08/2003
3	Anti-Bacterial Agents (Antibiotics)IBA 01/2016 - 04/2007
3	CathelicidinsIBA 11/2009 - 10/2005
2	Pharmaceutical PreparationsIBA 01/2019 - 06/2015
2	Complement System Proteins (Complement)IBA 01/2019 - 01/2016
2	Toll-Like Receptors (Toll-Like Receptor)IBA 11/2018 - 08/2003
2	Antimicrobial PeptidesIBA 11/2018 - 10/2005
1	Heterophile AntigensIBA 01/2019
1	AntibodiesIBA 01/2019
1	AntigensIBA 01/2019
1	Neoplasm Antigens (Tumor Antigens)IBA 01/2019
1	Complement C2 (Complement Component 2)IBA 01/2019
1	GalactosyltransferasesIBA 01/2019
1	GlycolipidsIBA 01/2019
1	VaccinesIBA 01/2019
1	Nicotinic Receptors (Nicotinic Acetylcholine Receptor)IBA 11/2018
1	DNA (Deoxyribonucleic Acid)IBA 11/2009
1	Proteins (Proteins, Gene)FDA Link 10/2006
1	Deoxyribonucleases (DNase)FDA Link 02/2006
1	ElementsIBA 10/2005
1	AcidsIBA 10/2005
1	polysaccharide intercellular adhesinIBA 05/2004
1	Lysine (L-Lysine)FDA Link 11/2003
1	Phospholipids (Phosphatides)FDA LinkGeneric 11/2003
1	Alanine (L-Alanine)FDA Link 11/2003
1	A 113IBA 08/2003
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 08/2003
1	Chemokine CXCL2IBA 08/2003

Therapy/Procedure

3	Therapeutics 01/2019 - 06/2015
2	Culture Diffusion Chambers 05/2004 - 08/2003
1	Immunotherapy 01/2019
1	Topical Administration 11/2018